3 news items
Rhythm Pharmaceuticals Announces Publication Of Results From Phase 2 Study Of Setmelanotide For The Treatment Of Hypothalamic Obesity In The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
=11). The publication also includes preliminary data from Rhythm's long-term extension of the Phase 2 study that were
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
(2.3) points or 45% for patients ≥12 years of age (n=11). The publication also includes preliminary data from Rhythm's long-term extension
Preview: Rhythm Pharmaceuticals's Earnings
RYTM
21 Feb 24
-week period, shares are up 88.95%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings
- Prev
- 1
- Next